Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers... Show more
Cardinal Health has progressively repositioned itself from a traditional pharmaceutical distributor into a diversified healthcare-services and infrastructure company. The centerpiece of that shift is its specialty strategy, which pairs core distribution with three physician-focused management services organization (MSO) platforms — oncology, urology, and autoimmune care — plus its fast-growing BioPharma Solutions commercialization business.
The competitive logic is structural: roughly 80%–90% of physicians in gastroenterology and urology remain unaffiliated with an MSO, leaving a large "white space" for bolt-on practice consolidation. Management has stated it does not need a fourth platform and instead plans to deepen existing verticals. This contrasts with peers McKesson and Cencora, which are pursuing broadly similar specialty expansion, meaning execution and margin discipline will determine relative outperformance.
At the same time, Cardinal Health is building scale in higher-margin adjacencies — Nuclear and Precision Health Solutions (including PET imaging and theranostics), at-Home Solutions, and OptiFreight Logistics. These businesses grew at a multiple of the core pharmaceutical segment and help diversify the earnings mix away from thin-margin drug distribution, though they carry higher integration risk as acquired assets are absorbed.
Cardinal Health's trajectory is tightly linked to healthcare utilization, demographics, and drug-pricing policy. An aging population supports the low-to-mid single-digit generic-volume baseline, while loss-of-exclusivity events in 2028–2029 are expected to provide constructive biosimilar and generic tailwinds.
Interest rates and inflation matter through two channels. Lower interest expense, supported by strong cash flow, is expected to aid fiscal 2027 earnings, while petroleum-based commodity costs and diesel prices pressure the Global Medical Products and Distribution segment. Management absorbed a $450 million tariff impact in fiscal 2026, mitigating about two-thirds through sourcing and operating actions — a reminder that trade policy remains a live variable.
On regulation, the Inflation Reduction Act's drug-pricing provisions create headline risk, but Cardinal Health's fee-for-service model and contractual protections have historically insulated its economics. Technology adoption — automation, advanced analytics, and digital ordering platforms — is emerging as a genuine efficiency lever across its distribution network.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps traders assess whether a stock, ETF, or other asset may trend bullish, bearish, or sideways over the coming week or month. It is designed to help users spot developing trends, evaluate potential breakouts or reversals, and explore predictions across a broad universe of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality to keep users informed of shifting signals. For investors tracking Cardinal Health alongside broader market momentum, the engine offers a data-driven way to monitor directional cues.
Looking into 2026 and beyond, Cardinal Health's long-term value creation rests on its 12%–14% EPS growth target and an ambition to scale BioPharma Solutions revenue from $550 million in fiscal 2025 toward $1 billion by fiscal 2028. Structural drivers include the fragmentation of specialty physician practices, rising adoption of complex therapies, and expanding at-home care.
Margin sustainability will hinge on mix shift toward specialty, nuclear, and at-home businesses, which carry higher profitability than core distribution, balanced against elevated commodity costs and integration expenses. Capital allocation priorities — roughly $700 million of annual capital expenditures, at least $1 billion in buybacks, and disciplined tuck-in M&A — signal a shareholder-friendly but operationally focused playbook.
Key long-term risks include intensifying competition from McKesson and Cencora, potential policy changes around drug pricing, and execution risk on multiple simultaneous acquisitions. Consensus analyst expectations remain constructive, but the story increasingly depends on converting specialty and at-home scale into durable, above-market profit growth rather than relying on outsized one-year demand.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CAH has been closely correlated with MCK. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if CAH jumps, then MCK could also see price increases.
| Ticker / NAME | Correlation To CAH | 1D Price Change % | ||
|---|---|---|---|---|
| CAH | 100% | -0.33% | ||
| MCK - CAH | 72% Closely correlated | -0.66% | ||
| COR - CAH | 62% Loosely correlated | -0.64% | ||
| HSIC - CAH | 7% Poorly correlated | +3.32% | ||
| AHG - CAH | 4% Poorly correlated | +3.17% | ||
| FOCL - CAH | 2% Poorly correlated | +9.15% | ||
More | ||||
a maker of pharmaceuticals, medical, surgical and laboratory supplies as well as develops drug delivery systems
Industry MedicalDistributors
The Moving Average Convergence Divergence (MACD) for CAH turned positive on November 04, 2026. Looking at past instances where CAH's MACD turned positive, the stock continued to rise in 36 of 43 cases over the following month. The odds of a continued upward trend are 84%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on CAH as a result. In 63 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
Following a +2.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAH advanced for three days, in 265 of 395 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 192 of 310 cases where CAH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
The 10-day RSI Indicator for CAH moved out of overbought territory on November 18, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In 22 of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at 52%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
CAH broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 6 (best 1 - 100 worst), indicating outstanding price growth. CAH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-21.824) is normal, around the industry mean (14.423). CAH has a moderately high P/E Ratio (37.376) as compared to the industry average of (11.188). Projected Growth (PEG Ratio) (1.105) is also within normal values, averaging (2.016). Dividend Yield (0.008) settles around the average of (0.134) among similar stocks. P/S Ratio (0.217) is also within normal values, averaging (4.260).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.